secwatch.observer — SEC 8-K summary
======================================

Issuer:     UNITED THERAPEUTICS Corp (UTHR)
CIK:        0001082554
Form:       8-K
Filed at:   2026-02-25T23:59:59+00:00
Accession:  0001082554-26-000007
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

United Therapeutics reports record $3.18B FY2025 revenue; EPS $27.86 diluted
----------------------------------------------------------------------------

- FY 2025 revenue hit record $3.18B (+11% YoY); net income $1.33B ($27.86 diluted EPS) vs $1.20B ($24.64) in 2024.
- Q4 revenue $790.2M (+7%); net income $364.3M ($7.70 diluted EPS) vs $301.3M ($6.19).
- Tyvaso DPI sales $1.29B (+25% YoY); total Tyvaso $1.88B (+16%).
- Orenitram sales $496.9M (+14% YoY).
- Repurchased $1.0B of stock in 2025; litigation accrual reduced to $3M from $71.1M in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1082554/000108255426000007/0001082554-26-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1082554/000108255426000007/uthr-20260225.htm
  HTML page:      https://secwatch.observer/filing/0001082554-26-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer